Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

This phase 3, randomized, controlled trial evaluated the efficacy and safety of mirvetuximab soravtansine (MIRV), an antibody drug conjugate targeting folate receptor α (FRα), compared to chemotherapy in patients with platinum resistant, FRα-positive ovarian cancer. The study involved 453 participants randomized to receive MIRV or investigator’s choice of chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan). Results demonstrated significantly improved progression free survival (median 5.62 vs. 3.98 months, P<0.001), objective response rate (42.3% vs. 15.9%, P<0.001), and overall survival (median 16.46 vs. 12.75 months, P=0.005) with MIRV. Adverse events were less frequent with MIRV (41.7% grade ≥3) than chemotherapy (54.1%). The findings support MIRV as a promising treatment for platinum resistant ovarian cancer with high FRα expression.

This phase 3, randomized, controlled trial evaluated the efficacy and safety of mirvetuximab soravtansine (MIRV), an antibody drug conjugate targeting folate receptor α (FRα), compared to chemotherapy in patients with platinum resistant, FRα-positive ovarian cancer. The study involved 453 participants randomized to receive MIRV or investigator’s choice of chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan). Results demonstrated significantly improved progression free survival (median 5.62 vs. 3.98 months, P<0.001), objective response rate (42.3% vs. 15.9%, P<0.001), and overall survival (median 16.46 vs. 12.75 months, P=0.005) with MIRV. Adverse events were less frequent with MIRV (41.7% grade ≥3) than chemotherapy (54.1%). The findings support MIRV as a promising treatment for platinum resistant ovarian cancer with high FRα expression.